The Journal of Heart and Lung Transplantation
Volume 27, Issue 5 , Pages 522-527 , May 2008

Myocardial HLA-G Reliably Indicates a Low Risk of Acute Cellular Rejection in Heart Transplant Recipients

  • Rohit Sheshgiri

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Nathalie Rouas-Freiss, PhD

      Affiliations

    • Service de Recherches en Hemato-Immunologie, CEA-DSV-DRM, Hopital Saint Louis, IUH, Paris, France.
    • ,
  • Vivek Rao, MD, PhD

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Jagdish Butany, MD

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Danny Ramzy, MD, PhD

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Irene Krawice-Radanne

      Affiliations

    • Service de Recherches en Hemato-Immunologie, CEA-DSV-DRM, Hopital Saint Louis, IUH, Paris, France.
    • ,
  • Heather J. Ross, MD, MHSc

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • ,
  • Edgardo D. Carosella, MD

      Affiliations

    • Service de Recherches en Hemato-Immunologie, CEA-DSV-DRM, Hopital Saint Louis, IUH, Paris, France.
    • ,
  • Diego H. Delgado, MD, MSc

      Affiliations

    • Heart Transplant Program, Peter Munk Cardiac Centre, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Diego Hernan Delgado, MD, Division of Cardiology, Department of Medicine, Toronto General Hospital, 585 University Avenue, NCSB 11C-1201, Toronto, ON M5G 2N2, Canada. Telephone: 416-340-3940. Fax: 416-340-4134.

Received 22 October 2007 ,Revised 20 January 2008 ,Accepted 6 February 2008.

References 

  1. Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248:220–223
  2. McMaster MT, Librach CL, Zhou Y, et al. Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol. 1995;154:3771–3778
  3. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA. 1997;94:11520–11525
  4. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, et al. A soluble HLA-G protein that inhibits natural killer cell–mediated cytotoxicity. Transplant Proc. 2001;33:2355–2359
  5. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA. 2004;101:7064–7069
  6. Le Rond S, Azema C, Krawice-Radanne I, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells. J Immunol. 2006;176:3266–3276
  7. Bainbridge D, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4+ T-lymphocytes. J Reprod Immunol. 2000;48:17–26
  8. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED. Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl Acad Sci USA. 2001;98:12150–12155
  9. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 2000;164:6100–6104
  10. Ishitani A, Geraghty DE. Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. Proc Natl Acad Sci USA. 1992;89:3947–3951
  11. Paul P, Cabestre FA, Ibrahim EC, et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol. 2000;61:1138–1149
  12. Carosella ED, Moreau P, Le Maoult J, et al. HLA-G molecules: from maternal–fetal tolerance to tissue acceptance. Adv Immunol. 2003;81:199–252
  13. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res. 2005;65:10139–10144
  14. Rouas-Freiss N, LeMaoult J, Moreau P, Dausset J, Carosella ED. HLA-G in transplantation: a relevant molecule for inhibition of graft rejection?. Am J Transplant. 2003;3:11–16
  15. Creput C, Durrbach A, Menier C, et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver–kidney transplantation. J Hepatol. 2003;39:587–594
  16. Lila N, Carpentier A, Amrein C, et al. Implication of HLA-G molecule in heart-graft acceptance. Lancet. 2000;355:2138
  17. Lila N, Amrein C, Guillemain R, et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation. 2002;105:1949–1954
  18. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24:1710–1720
  19. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 1986;137:2299–2306
  20. Paul P, Rouas-Freiss N, Moreau P, et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol. 2000;61:1177–1195
  21. Menier C, Saez B, Horejsi V, et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003;64:315–326
  22. Hviid TV, Hylenius S, Rørbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics. 2003;55:63–79
  23. Rebmann V, van der Ven K, Passler M, et al. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens. 2001;57:15–21
  24. Luque J, Torres MI, Aumente MD, et al. sHLA-G levels in the monitoring of immunosuppressive therapy and rejection following heart transplantation. Transplant Immunol. 2006;17:70–73
  25. Luque J, Torres MI, Aumente MD, et al. Soluble HLA-G in heart transplantation: their relationship to rejection episodes and immunosuppressive therapy. Hum Immunol. 2006;67:257–263
  26. Lila N, Amrein C, Guillemain R, et al. Soluble human leukocyte antigen-G: a new strategy for monitoring acute and chronic rejections after heart transplantation. J Heart Lung Transplant. 2007;26:421–422
  27. Bastürk B, Karakayali F, Emiroglu R, et al. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc. 2006;38:571–574
  28. Creput C, Le Friec G, Bahri R, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver–kidney transplantation: possible implications for monitoring patients. Hum Immunol. 2003;64:1033–1038
  29. Qiu J, Terasaki PI, Miller J, et al. Soluble HLA-G expression and renal graft acceptance. Am J Transplant. 2006;6:2152–2156
  30. Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant. 2005;24:1289–1296

PII: S1053-2498(08)00137-X

doi: 10.1016/j.healun.2008.02.004

The Journal of Heart and Lung Transplantation
Volume 27, Issue 5 , Pages 522-527 , May 2008

Article Tools

* Image Usage & Resolution